Abstract
Background:
Head and neck squamous cell carcinoma (HNSCC) is an aggressive malignancy that is now the sixth most common neoplasm in the world. Despite numerous advances in treatment, the long-term survival has remained the same for the last 25 years. Angiogenesis has been shown to be important for HNSCC tumour growth and metastasis. Therefore, inhibitors of angiogenesis are a new class of anti-neoplastic substances that might be a powerful complement to conventional therapy in HNSCC.
Material and methods:
The role of angiogenesis in HNSCC as well as preclinical and clinical trials concerning inhibitors of tumor-angiogenesis are discussed here.
Results:
Many of the investigated angiogenesis inhibitors demonstrated anti-tumor effects in preclinical and clinical trials. In a few cases, partial remission was observed.
Conclusions:
Anti-angiogenic therapy will undoubtly have the potential to change standard tumor therapies. Some anti-angiogenic substances appear to be promising candidates for a clinical use in the therapy of HNSCC.
Publication types
-
Comparative Study
-
English Abstract
-
Review
MeSH terms
-
Adult
-
Angiogenesis Inducing Agents
-
Angiogenesis Inhibitors / administration & dosage
-
Angiogenesis Inhibitors / therapeutic use*
-
Angiostatins
-
Animals
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / therapeutic use
-
Carcinoma, Squamous Cell / drug therapy*
-
Carcinoma, Squamous Cell / metabolism
-
Carcinoma, Squamous Cell / pathology
-
Carcinoma, Squamous Cell / physiopathology
-
Clinical Trials as Topic
-
Extracellular Matrix / metabolism
-
Female
-
Head and Neck Neoplasms / drug therapy*
-
Head and Neck Neoplasms / metabolism
-
Head and Neck Neoplasms / pathology
-
Head and Neck Neoplasms / physiopathology
-
Humans
-
Male
-
Metalloendopeptidases / metabolism
-
Mice
-
Neoplasm Metastasis
-
Neovascularization, Pathologic
-
Peptide Fragments / administration & dosage
-
Peptide Fragments / therapeutic use
-
Plasminogen / administration & dosage
-
Plasminogen / therapeutic use
-
Time Factors
Substances
-
Angiogenesis Inducing Agents
-
Angiogenesis Inhibitors
-
Antineoplastic Agents
-
Peptide Fragments
-
Angiostatins
-
Plasminogen
-
Metalloendopeptidases